Shares of Dyne Therapeutics, Inc. (DYN) plunged 5.22% in the intraday session on Monday, following the company's disappointing Q4 2024 earnings report last week.
The biotech firm reported a higher-than-expected loss of $0.88 per share for the quarter ended December 31, 2024, missing analysts' average estimate of a $0.96 loss per share. Revenues for the quarter came in at zero, in line with expectations.
The wider losses appear to have dampened investor sentiment, sparking a selloff in Dyne's shares. The stock has already fallen a staggering 42.2% so far this quarter amid concerns over the company's cash burn and ability to bring new therapies to market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。